SCHEMBL6169441

SCHEMBL6169441

Cc1noc(-c2cccc(Cl)c2)c1-c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.55
CA1 P00915 5/20 0.55
CA4 P22748 2/20 0.49
CA7 P43166 2/20 0.49
PTGS2 P35354 12/20 0.49
PTGS1 P23219 4/20 0.49
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
MT-CO2 P00403 1/20 0.49
LMNA P02545 1/20 0.49
CA3 P07451 1/20 0.49
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49
CYP3A4 P08684 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CHRM1 P11229 1/20 0.49
ADRA2B P18089 1/20 0.49
CA6 P23280 1/20 0.49
SLC6A2 P23975 1/20 0.49
PDE4A P27815 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6170551 0.86 CA1 (0.54) CA2CA1CA4CA7PTGS2
SCHEMBL6170394 0.86 CA1 (0.54) CA2CA1CA4CA7PTGS2
SCHEMBL6013960 0.84 PTGS2 (0.63) CA2CA1CA4CA7PTGS2
SCHEMBL6169136 0.84 PTGS2 (0.63) CA2CA1CA4CA7PTGS2
SCHEMBL6170416 0.83 PTGS1 (0.60) PTGS2PTGS1BRD4BRD2
SCHEMBL8474223 0.81 KMT2A (0.48) CA2CA1CA4CA7PTGS2
SCHEMBL6169347 0.81 PTGS2 (0.73) CA2CA1CA4CA7PTGS2
SCHEMBL6169868 0.80 CA2 (0.56) CA2CA1CA4CA7PTGS2
SCHEMBL6168306 0.80 CA2 (0.56) CA2CA1CA4CA7PTGS2
SCHEMBL6169079 0.78 PTGS2 (0.64) CA2CA1CA4CA7PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP claimed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP claimed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP claimed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP claimed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO claimed
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP disclosed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN disclosed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN disclosed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP disclosed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 CN disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed